The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Nakamoto Inc. (NAKA) appointed Odyssey Transfer and Trust Company as successor warrant agent, effective October 1, 2026, and as transfer agent and registrar; the company transferred its registered common shares and related records from VStock Transfer, LLC. The amended agreement leaves warrant economics unchanged: it does not change exercise prices, shares issuable upon exercise, or the June 3, 2029 expiration date, except as permitted in connection with the 1-for-40 reverse stock split effective May 22, 2026. As of October 1, 2026, all outstanding warrants were held in book-entry form through The Depository Trust Company and evidenced by global certificates; none was certificated.
Nakamoto Inc. (NAKA) reported that director and Chief Investment Officer Evans Tyler Matthew sold 982 shares of Common Stock on September 15, 2026 at $7.63 per share. According to the company’s disclosure, this sale occurred upon partial vesting of a restricted stock unit award and was made solely to satisfy associated tax withholding obligations, leaving the reporting person with 576,764 directly held shares.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (NAKA) reported equity transactions by director and Chief Investment Officer Evans Tyler Matthew. He received a grant of 250,000 stock options with a $7.06 exercise price, bringing his option holdings to 885,544. He was also granted 56,657 RSUs with a two-year vesting schedule.
In connection with merger agreements, 230 common shares were forfeited and cancelled for no consideration and 3 common shares were issued. All reported share amounts reflect a 1-for-40 reverse stock split of Nakamoto Inc. common stock.